ClinicalTrials.gg
CompletedNCT03120949CREDO 4Updated Oct 12, 2023Results posted

Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis

A Phase 3 interventional study of Olokizumab 64 mg SC q4w and Olokizumab 64 mg SC q2w in Rheumatoid Arthritis, sponsored by R-Pharm International, LLC. Completed at 239 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-12.

Sponsored by R-Pharm International, LLC (part of R-Pharm) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.

Enrollment
Largest of 10
2,106 · median 206
Started
2017
with 1 other
Phase 3
4 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
5 of 10
R-Pharm International, LLC

Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one has the largest enrollment, is one of 2 that started in 2017, is one of 4 in phase 3, and was the 9th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →

About olokizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing olokizumab in Arthritis, Rheumatoid as a file.
02

Study summary

The primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) in subjects with moderately to severely active rheumatoid arthritis (RA) who previously had completed 24 weeks of double-blind treatment in Study CREDO 1, 2 or 3 (core studies). The long-term efficacy, immunogenicity, the physical function and quality of life of subjects received long-term treatment with OKZ were assessed as well.

Read the detailed description

This OLE study (CL04041024) included an 82-week open-label Treatment Period that followed completion of one of the core studies (Study CREDO 1, 2 or 3). The OLE open-label Treatment Period lasted from Visit 1 (OLE Baseline/Week 24) to Visit 10 (End of Treatment (EoT)/Week 106), followed by a 20-week Safety Follow-Up Period from Week 106 to Week 126. The first visit of the OLE study was the same visit as the Week 24 visit in the core studies.

Subjects were randomized to 1 of the 2 OKZ treatment groups in the OLE study based on the treatment received in the core studies. Subjects who had received OKZ (q2w or q4w) in the core study in which they had participated (including subjects who received placebo in Study CREDO 3 and were re-randomized to OKZ at Week 16) received the same OKZ treatment regimen in the OLE study. Subjects who had received placebo (Study CREDO 1 and CREDO 2) or adalimumab (Study CREDO 2) in the core study in which they had participated were randomized in a 1:1 ratio to OKZ 64 mg q2w or OKZ 64 mg q4w regimens in the OLE study.

For the first 12 weeks of the OLE, all subjects were required to remain on a stable dose of background methotrexate (MTX) at 15 to 25 mg/week (or≥10 mg/week if there was documented intolerance to higher doses) with a stable route of administration (oral, SC, or intramuscular (IM)). After 12 weeks (Visit 4 [Week 36] of the OLE study), the Investigator might adjust the MTX dosage and route, per local guidelines. Methotrexate might be adjusted only for safety reasons according to Investigator discretion before Visit 4 (Week 36) of the OLE study.

Subjects who had been on rescue disease-modifying anti-rheumatic drugs (DMARDs) during the core studies were asked to continue these medications for the first 12 weeks of the OLE study. The Investigator could adjust these background medications if deemed appropriate after Visit 4 (Week 36) of the OLE study. Background rescue therapy might be adjusted only for safety reasons according to Investigator discretion before Visit 4 (Week 36) of the OLE study.

Throughout the study, concomitant treatment with folic acid ≥ 5 mg per week or equivalent was required for all subjects.

Subjects returned to the study site periodically for safety and response assessments as per the Schedule of Events.

The last dose of open-label study treatment in the OLE study was administered at Week 104 for all subjects. After completion of the 82-week open-label Treatment Period, subjects entered the 20-week Safety Follow-Up Period. During the Safety Follow-Up Period, subjects returned for 3 visits at +4, +8, and +22 weeks after the last dose of study treatment.

Subjects who discontinued the open-label treatment prematurely required to come for the EoT Visit 2 weeks after the last study treatment administration and then return for the 3 Safety Follow-Up Visits +4, +8, and +22 weeks after the last study treatment administration.

Adverse events were assessed throughout the study period and evaluated using the Common Technology Criteria version 4.0 (CTCAE v 4.0).

There were ongoing monitoring of safety events, including laboratory findings by the Sponsor or its designee. In addition, safety parameters were assessed throughout the study by an independent Data Safety Monitoring Board (DSMB).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • moderate
  • severe
  • subcutaneous
  • Olokizumab
  • open-label
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects may be enrolled in the study only if they meet all of the following criteria:

  1. Subject must be willing and able to sign
  2. Subject must have completed the 24-week double-blind Treatment Period in 1 of the 3 core studies (CL04041022, CL04041023, or CL04041025).
  3. Subject must have maintained their stable dose (and route) of MTX 15 to 25 mg/week (or ≥ 10 mg/week if there is documented intolerance to higher doses) during the core study and plan to maintain the same dose and route of administration for ≥ 12 additional weeks
  4. Subjects must be willing to take folic acid or equivalent throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. Subject with any medically important condition in the core study (e.g., laboratory values, frequent Adverse events (AEs) or serious adverse events (SAEs), infection SAEs, and/or other concurrent severe and/or uncontrolled medical condition) which would make this subject unsuitable for inclusion in the open-label extension (OLE) study in the Investigator's judgement.
  2. Subject has evidence of active tuberculosis (TB)
  3. Subject with a positive or repeated indeterminate interferon-gamma release assay (IGRA) result at Week 22 of the core study

    • Subjects may be enrolled in the OLE study if they fulfill all 3 of the following criteria prior to the first dose of study treatment:
    1. Active TB is ruled out by a certified TB specialist or pulmonologist who is familiar with diagnosing and treating TB (as acceptable per local practice);
    2. The subject starts prophylaxis for latent TB infection (LTBI) according to country-specific/Centers for Disease Control and Prevention (CDC) guidelines (treatment with isoniazid for 6 months is not an appropriate prophylactic regime for this study and it should not be used); and
    3. The subject is willing to complete the entire course of recommended LTBI therapy.
  4. Subject has planned surgery during the first 12 weeks of the OLE study
  5. Female subjects who are pregnant or who are planning to become pregnant during the study or within 6 months of the last dose of study drug
  6. Female subjects of (unless permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of natural amenorrhea as defined by the amenorrhea with underlying status [e.g., correlative age] or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone levels >40 mIU/mL and estradiol \<20 pg/mL) who are not willing to use a highly effective method of during the study and for at least 6 months after the last administration of study treatment OR Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment.

    Highly effective contraception is defined as:

    • Female sterilization surgery: hysterectomy, surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks prior to the first dose of study treatment in the core study

      • In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by documented follow-up hormone level assessment
    • Total abstinence if it is the preferred and constant lifestyle of the subject. Thus, periodic abstinence such as ovulation, symptothermal, postovulation, calendar methods, and withdrawal are not acceptable methods of contraception.
    • Male sterilization surgery: at least 6 months prior to the first dose of study treatment in the core study (with the appropriate postvasectomy documentation of the absence of sperm in the ejaculate). For female subjects, the vasectomized male should be the only partner.
    • Placement of established intrauterine device (IUD): IUD copper or IUD with progesterone
    • Barrier method (condom and intravaginal spermicide, cervical caps with spermicide, or diaphragm with spermicide) in combination with the following: established oral, injected, or implanted hormone methods of contraception or contraceptive patch.
  7. Subject is unwilling or unable to follow the procedures outlined in the protocol.
  8. Other medical or psychiatric conditions, or laboratory abnormalities that may increase the potential risk associated with study participation and administration of the study treatment, or that may affect study results interpretation and, as per Investigator's judgement, make the subject ineligible.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,106 participants (actual)

Study arms

  • Experimental
    Treatment Arm 1: OKZ 64 mg q4w + MTX

    Olokizumab 64 mg SC q4w + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular).

    Drug: Olokizumab 64 mg SC q4w · Drug: Concomitant treatment

  • Experimental
    Treatment Arm 2: OKZ 64 mg q2w + MTX

    Olokizumab 64 mg SC q2w + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular).

    Drug: Olokizumab 64 mg SC q2w · Drug: Concomitant treatment

Interventions

  • 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.

  • 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.

  • DrugConcomitant treatment

    Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.) Folic acid ≥ 5 mg per week or equivalent

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population)

    Incidence of Treatment-Emergent Adverse Events Reported for ≥5% of Subjects in Any Treatment Group by System Organ Class or Preferred Term

    Time frame: up to Week 126

  2. Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population)

    Incidence of Serious Treatment-Emergent Adverse Events by System Organ Class or Preferred Term. Deaths are included.

    Time frame: up to Week 126

  3. Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI)

    Time frame: up to Week 126

  4. Incidence of Treatment-Emergent AEs Leading to Withdrawal of the Study Treatment

    Time frame: up to Week 126

  5. Incidence Rate of Treatment Emergent AEs Per Patient-years of Exposure

    Incidence Rate of all Subjects with at Least One Treatment Emergent AE. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.

    Time frame: up to Week 126

  6. Incidence Rate of Treatment Emergent SAEs Per Patient-years of Exposure

    Incidence Rate of all Subjects with at Least One Treatment Emergent SAE. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.

    Time frame: up to Week 126

  7. Incidence Rate of Treatment Emergent AESIs (Safety Population)

    Incidence Rate of all Subjects with at Least One Treatment Emergent AESI. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.

    Time frame: up to Week 126

Secondary outcomes

  1. American College of Rheumatology 20% (ACR20) Response Rates Compare Against Core Baseline Through Week 82

    Number and Proportion of subjects achieving an ACR20 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)

    Time frame: up to Week 82

  2. American College of Rheumatology 50% (ACR50) Response Rates Compare Against Core Baseline Through Week 82

    Number and Proportion of subjects achieving an ACR50 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82 American College of Rheumatology 50 % response is a composite defined as a ≥ 50% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥ 50% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)

    Time frame: up to Week 82

  3. American College of Rheumatology 70% (ACR70) Response Rates Compare Against Core Baseline Through Week 82

    Number and Proportion of subjects achieving an ACR70 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82 American College of Rheumatology 70 % response is a composite defined as a ≥ 70% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥ 70% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)

    Time frame: up to Week 82

  4. Proportion of Subjects With Simplified Disease Activity Index (SDAI) Remission Through Week 82

    The number and proportion of subjects with SDAI score ≤ 3.3 (considered to be in remission). The SDAI was calculated in the statistical database for analysis purposes using the SJC (28 joints), TJC (28 joints), CRP (mg/dL), the Patient Global Assessment of Disease Activity (VAS) (in cm), and the Physician Global Assessment (VAS) (in cm) according to the following formula: SJC + TJC + Patient Global Assessment of Disease Activity (VAS) + Physician Global Assessment (VAS) + CRP (mg/dL)

    Time frame: up to week 82

  5. Disease Activity Score 28-joint Count (DAS28) Response Rates Through Week 82

    Number and Proportion of subjects with DAS28 low disease activity (based on DAS28 C-reactive protein (CRP) \< 3.2), who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82. The DAS28 (CRP) was calculated in the statistical database for analysis purposes using the Swollen joint count (SJC) (28 joints), Tender joint count (TJC) (28 joints), CRP level, and the Patient Global Assessment of Disease Activity Visual Analog Scale (VAS) (100 mm VAS, where 0 is "no disease activity" and 100 was "maximal disease activity") according to the following formula: \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.36 × natural log (CRP+1)\] + \[0.014 × VAS\] + 0.96.

    Time frame: up to Week 82

  6. Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 12

    HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

    Time frame: Core baseline, Week 12

  7. Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 20

    HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

    Time frame: Core baseline, Week 20

  8. Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 28

    HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

    Time frame: Core baseline, Week 28

  9. Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 40

    HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

    Time frame: Core baseline, Week 40

  10. Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 52

    HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

    Time frame: Core baseline, Week 52

  11. Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 64

    HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

    Time frame: Core baseline, Week 64

  12. Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 82

    HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

    Time frame: Core baseline, Week 82

  13. Proportion of Subjects With Health Assessment Questionnaire - Disability Index (HAQ-DI) Improvement Through Week 82

    The number and proportion of subjects with HAQ-DI improvement ≥ 0.22 Against OLE Baseline. HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

    Time frame: up to week 82

  14. Changes From Core Baseline Over Time in Clinical Disease Activity Index (CDAI)

    CDAI Range: 0 (the best outcome) - 76 (the worst outcome), with a decrease from baseline indicating improvement. The CDAI was calculated in the statistical database for analysis purposes using the SJC (28 joints), TJC (28 joints), the Patient Global Assessment of Disease Activity (VAS) (in cm), and the Physician Global Assessment (VAS) (in cm) according to the following formula: CDAI = SJC + TJC + Patient Global Assessment of Disease Activity (VAS) + Physician Global Assessment (VAS)

    Time frame: up to week 82

07

Results

Posted Jun 7, 2022

Participant flow

Enrollment was conducted at 241 sites in 18 countries (Argentina, Belarus, Bulgaria, Brazil, Colombia, Czech Republic, Germany, Estonia, United Kingdom, Hungary, South Korea, Lithuania, Latvia, Mexico, Poland, Russia, Taiwan, United States). A total of 2105 subjects who had previously completed 24 weeks of double-blind treatment in a core study were randomized. All except one randomized subject received OKZ treatment. A total of 2104 subjects were analyzed for efficacy in the mITT Population.

Participant flow — Overall Study
MilestoneTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Started10581047
Mitt10571047
Safety population10431061
Completed830844
Not completed228203
Withdrew: Randomized in error10
Withdrew: Death1313
Withdrew: Lost to follow-up2313
Withdrew: Withdrawal by subject139124
Withdrew: Covid-194334
Withdrew: Patient moved out of residence and was not able to come to the site13
Withdrew: Lack of discipline in adhering to the schedule of visits, difficult cooperation with the patient10
Withdrew: Safety follow-up visit (sfu)-3 was performed by phone due to family reasons10
Withdrew: Patient completed the treatment, but could not come for follow-up visits due to another city moving10
Withdrew: Site was closed23
Withdrew: Study coordinator error, patient started a biologic and study coordinator forgot to complete sfu10
Withdrew: Principal investigator (pi) decision, the pi starting subject on another biologic medication01
Withdrew: Pi terminated subject from ip (ae's abnormal wbc, abnormal absolute neutrophils lab)10
Withdrew: Patient was hospitalized due to the sae and couldn't visit the site for sfu-310
Withdrew: Other: adverse event01
Withdrew: Due to the death of his wife, he refused to participate in follow up 301
Withdrew: Follow up visit not performed (patient outside residence)02
Withdrew: Subject refusal to attend visit01
Withdrew: Personal reasons01
Withdrew: Pi did not feel it was best for subject to be without treatment for 12 weeks.01
Withdrew: Lack of efficacy (pi perspective) end of study visit01
Withdrew: Compliance with medication01
Withdrew: Subject has a severe or life threatening infection that requires hospitalization per medical monitor01
Withdrew: Other: protocol violation (refused from sfu visits)01
Withdrew: Study terminated by principal investigator01

Outcome measures

PrimaryIncidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population)

Incidence of Treatment-Emergent Adverse Events Reported for ≥5% of Subjects in Any Treatment Group by System Organ Class or Preferred Term

Time frame:
up to Week 126
Reported as:
Count of participants · Participants
Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population)
ParticipantsTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Infections and infestations401408
Infections and infestations: Nasopharyngitis7187
Infections and infestations: Upper respiratory tract infection5967
Infections and infestations: Bronchitis5945
Investigations284290
Investigations: Alanine aminotransferase increased97118
Investigations: Aspartate aminotransferase increased5263
Musculoskeletal and connective tissue disorders149152
Blood and lymphatic system disorders125147
Blood and lymphatic system disorders: Leukopenia4660
Blood and lymphatic system disorders: Neutropenia4257
Metabolism and nutrition disorders113135
Gastrointestinal disorders100118
Injury, poisoning and procedural complications10195
Skin and subcutaneous tissue disorders8894
Nervous system disorders6081
Respiratory, thoracic and mediastinal disorders6068
Vascular disorders6068
General disorders and administration site conditions5465
PrimaryIncidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population)

Incidence of Serious Treatment-Emergent Adverse Events by System Organ Class or Preferred Term. Deaths are included.

Time frame:
up to Week 126
Reported as:
Count of participants · Participants
Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population)
ParticipantsTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Number of Subjects with at Least One SAE129120
Infections and infestations4047
Infections and infestations: Pneumonia77
Infections and infestations: Cellulitis74
Infections and infestations: Erysipelas54
Infections and infestations: COVID-1913
Infections and infestations: Pyelonephritis acute22
Infections and infestations: COVID-19 pneumonia21
Infections and infestations: Pyelonephritis21
Infections and infestations: Sepsis03
Infections and infestations: Abscess limb11
Infections and infestations: Diverticulitis11
Infections and infestations: Osteomyelitis11
Infections and infestations: Abdominal wall abscess01
Infections and infestations: Abscess soft tissue01
Infections and infestations: Acute sinusitis01
Infections and infestations: Atypical pneumonia10
Infections and infestations: Bartholinitis01
Infections and infestations: Bronchitis01
Infections and infestations: Bullous erysipelas10
Infections and infestations: Bursitis infective01
Infections and infestations: Cat scratch disease01
Infections and infestations: Dengue fever01
Infections and infestations: Device related infection01
Infections and infestations: Device related sepsis01
Infections and infestations: Encephalomyelitis01
Infections and infestations: Gangrene01
Infections and infestations: Gastroenteritis01
Infections and infestations: Influenza01
Infections and infestations: Intervertebral discitis10
Infections and infestations: Joint abscess10
Infections and infestations: Latent tuberculosis01
Infections and infestations: Localised infection10
Infections and infestations: Lower respiratory tract infection01
Infections and infestations: Ludwig angina10
Infections and infestations: Medical device site abscess01
Infections and infestations: Necrotising fasciitis01
Infections and infestations: Necrotising soft tissue infection01
Infections and infestations: Post procedural infection10
Infections and infestations: Pulmonary tuberculosis01
Infections and infestations: Renal abscess10
Infections and infestations: Salpingo-oophoritis10
Infections and infestations: Scrotal abscess10
Infections and infestations: Septic shock01
Infections and infestations: Streptococcal sepsis10
Infections and infestations: Tonsillitis01
Infections and infestations: Urinary tract infection01
Infections and infestations: Viral infection01
Infections and infestations: Viral upper respiratory tract infection10
Infections and infestations: Wound infection pseudomonas10
Musculoskeletal and connective tissue disorders1411
Musculoskeletal and connective tissue disorders: Osteoarthritis66
Musculoskeletal and connective tissue disorders: Osteonecrosis11
Musculoskeletal and connective tissue disorders: Rheumatoid arthritis11
Musculoskeletal and connective tissue disorders: Arthritis10
Musculoskeletal and connective tissue disorders: Bursitis10
Musculoskeletal and connective tissue disorders: Cervical spinal stenosis01
Musculoskeletal and connective tissue disorders: Foot deformity01
Musculoskeletal and connective tissue disorders: Intervertebral disc protrusion10
Musculoskeletal and connective tissue disorders: Joint ankylosis01
Musculoskeletal and connective tissue disorders: Muscle contracture10
Musculoskeletal and connective tissue disorders: Musculoskeletal chest pain10
Musculoskeletal and connective tissue disorders: Spinal osteoarthritis10
Injury, poisoning and procedural complications814
Injury, poisoning and procedural complications: Clavicle fracture11
Injury, poisoning and procedural complications: Femoral neck fracture02
Injury, poisoning and procedural complications: Head injury20
Injury, poisoning and procedural complications: Hip fracture02
Injury, poisoning and procedural complications: Acetabulum fracture01
Injury, poisoning and procedural complications: Arthropod bite10
Injury, poisoning and procedural complications: Comminuted fracture01
Injury, poisoning and procedural complications: Concussion01
Injury, poisoning and procedural complications: Extradural haematoma10
Injury, poisoning and procedural complications: Femur fracture10
Injury, poisoning and procedural complications: Foot fracture01
Injury, poisoning and procedural complications: Humerus fracture01
Injury, poisoning and procedural complications: Lower limb fracture01
Injury, poisoning and procedural complications: Multiple injuries10
Injury, poisoning and procedural complications: Muscle rupture10
Injury, poisoning and procedural complications: Overdose01
Injury, poisoning and procedural complications: Post procedural complication01
Injury, poisoning and procedural complications: Thoracic vertebral fracture01
Injury, poisoning and procedural complications: Traumatic intracranial haematoma01
Injury, poisoning and procedural complications: Wrist fracture01
Cardiac disorders1110
Cardiac disorders: Acute myocardial infarction30
Cardiac disorders: Arrhythmia11
Cardiac disorders: Atrial fibrillation02
Cardiac disorders: Acute coronary syndrome01
Cardiac disorders: Angina unstable10
Cardiac disorders: Atrioventricular block complete10
Cardiac disorders: Atrioventricular block second degree10
Cardiac disorders: Bradycardia01
Cardiac disorders: Cardiac arrest10
Cardiac disorders: Cardiac failure chronic01
Cardiac disorders: Cardiac failure congestive01
Cardiac disorders: Coronary artery occlusion10
Cardiac disorders: Coronary artery stenosis01
Cardiac disorders: Myocardial infarction01
Cardiac disorders: Right ventricular dysfunction01
Cardiac disorders: Sinus tachycardia01
Cardiac disorders: Stress cardiomyopathy10
Cardiac disorders: Supraventricular tachyarrhythmia01
Cardiac disorders: Ventricular fibrillation10
Gastrointestinal disorders812
Gastrointestinal disorders: Diverticular perforation12
Gastrointestinal disorders: Abdominal pain11
Gastrointestinal disorders: Colitis11
Gastrointestinal disorders: Gastritis erosive02
Gastrointestinal disorders: Abdominal hernia obstructive10
Gastrointestinal disorders: Dyspepsia01
Gastrointestinal disorders: Gastric polyps10
Gastrointestinal disorders: Gastric ulcer01
Gastrointestinal disorders: Gastrointestinal disorder01
Gastrointestinal disorders: Intestinal obstruction01
Gastrointestinal disorders: Obstructive pancreatitis10
Gastrointestinal disorders: Pancreatitis acute01
Gastrointestinal disorders: Pancreatitis chronic10
Gastrointestinal disorders: Peptic ulcer10
Gastrointestinal disorders: Salivary gland calculus01
Neoplasms benign, malignant and unspecified (incl cysts and polyps)118
Neoplasms benign, malignant and unspecified: Meningioma11
Neoplasms benign, malignant and unspecified: Benign neoplasm of thyroid gland10
Neoplasms benign, malignant and unspecified: Central nervous system neoplasm01
Neoplasms benign, malignant and unspecified: Cervix carcinoma stage II10
Neoplasms benign, malignant and unspecified: Clear cell renal cell carcinoma10
Neoplasms benign, malignant and unspecified: Colon cancer10
Neoplasms benign, malignant and unspecified: Endometrial adenocarcinoma10
Neoplasms benign, malignant and unspecified: Endometrial cancer01
Neoplasms benign, malignant and unspecified: Extranodal marginal zone B-cell lymphoma (MALT type)01
Neoplasms benign, malignant and unspecified: Gastric cancer10
Neoplasms benign, malignant and unspecified: Invasive ductal breast carcinoma01
Neoplasms benign, malignant and unspecified: Lung adenocarcinoma stage III10
Neoplasms benign, malignant and unspecified: Malignant melanoma10
Neoplasms benign, malignant and unspecified: Marginal zone lymphoma01
Neoplasms benign, malignant and unspecified: Meningioma benign10
Neoplasms benign, malignant and unspecified: Metastatic neoplasm10
Neoplasms benign, malignant and unspecified: Pancreatic carcinoma metastatic01
Neoplasms benign, malignant and unspecified: Salivary gland cancer10
Neoplasms benign, malignant and unspecified: Uterine leiomyoma01
Nervous system disorders136
Nervous system disorders: Cerebrovascular accident42
Nervous system disorders: Dizziness11
Nervous system disorders: Ischaemic stroke02
Nervous system disorders: Syncope20
Nervous system disorders: Carotid artery aneurysm10
Nervous system disorders: Encephalopathy10
Nervous system disorders: Migraine10
Nervous system disorders: Myelopathy10
Nervous system disorders: Paraesthesia10
Nervous system disorders: Pineal gland cyst10
Nervous system disorders: Seizure10
Nervous system disorders: Subarachnoid haemorrhage01
Nervous system disorders: Transient ischaemic attack10
Respiratory, thoracic and mediastinal disorders712
Respiratory, thoracic and mediastinal disorders: Pulmonary embolism24
Respiratory, thoracic and mediastinal disorders: Chronic obstructive pulmonary disease11
Respiratory, thoracic and mediastinal disorders: Pulmonary fibrosis11
Respiratory, thoracic and mediastinal disorders: Respiratory failure11
Respiratory, thoracic and mediastinal disorders: Asthmatic crisis10
Respiratory, thoracic and mediastinal disorders: Bronchitis chronic01
Respiratory, thoracic and mediastinal disorders: Chronic respiratory failure01
Respiratory, thoracic and mediastinal disorders: Chylothorax01
Respiratory, thoracic and mediastinal disorders: effusion10
Respiratory, thoracic and mediastinal disorders: Pleurisy01
Respiratory, thoracic and mediastinal disorders: Pneumothorax01
Investigations96
Investigations: Alanine aminotransferase increased75
Investigations: Hepatic enzyme increased11
Investigations: Liver function test increased10
Hepatobiliary disorders63
Hepatobiliary disorders: Cholelithiasis21
Hepatobiliary disorders: Cholecystitis chronic11
Hepatobiliary disorders: Biliary colic10
Hepatobiliary disorders: Hepatotoxicity10
Hepatobiliary disorders: Hyperplastic cholecystopathy01
Hepatobiliary disorders: Liver injury10
General disorders and administration site conditions44
General disorders and administration site conditions: Death11
General disorders and administration site conditions: Sudden death11
General disorders and administration site conditions: Lithiasis10
General disorders and administration site conditions: Pyrexia01
General disorders and administration site conditions: Sudden cardiac death10
General disorders and administration site conditions: Vascular stent occlusion01
Reproductive system and breast disorders33
Reproductive system and breast disorders: Uterine polyp20
Reproductive system and breast disorders: Endometrial hyperplasia01
Reproductive system and breast disorders: Female genital tract fistula01
Reproductive system and breast disorders: Genital haemorrhage10
Reproductive system and breast disorders: Intermenstrual bleeding01
Reproductive system and breast disorders: Ovarian cyst01
Skin and subcutaneous tissue disorders42
Skin and subcutaneous tissue disorders: Dermatitis11
Skin and subcutaneous tissue disorders: Skin ulcer11
Skin and subcutaneous tissue disorders: Dermatitis contact10
Skin and subcutaneous tissue disorders: Erythema10
Vascular disorders42
Vascular disorders: Deep vein thrombosis10
Vascular disorders: Hypertensive crisis10
Vascular disorders: Peripheral artery occlusion01
Vascular disorders: Shock haemorrhagic10
Vascular disorders: Thrombophlebitis01
Vascular disorders: Varicose vein10
Renal and urinary disorders32
Renal and urinary disorders: Calculus urinary10
Renal and urinary disorders: Nephritis10
Renal and urinary disorders: Nephrolithiasis01
Renal and urinary disorders: Renal colic10
Renal and urinary disorders: Ureterolithiasis01
Blood and lymphatic system disorders12
Blood and lymphatic system disorders: Febrile neutropenia01
Blood and lymphatic system disorders: Lymphadenopathy10
Blood and lymphatic system disorders: Splenic cyst01
Pregnancy, puerperium and perinatal conditions21
Pregnancy, puerperium and perinatal conditions: Abortion spontaneous10
Pregnancy, puerperium and perinatal conditions: Abortion threatened10
Pregnancy, puerperium and perinatal conditions: Ectopic pregnancy01
Ear and labyrinth disorders11
Ear and labyrinth disorders: Deafness neurosensory01
Ear and labyrinth disorders: Vestibular disorder10
Eye disorders02
Eye disorders: Cataract01
Eye disorders: Ocular myasthenia01
Immune system disorders10
Immune system disorders: Hypersensitivity10
Psychiatric disorders10
Psychiatric disorders: Completed suicide10
PrimaryIncidence of Treatment-Emergent Adverse Events of Special Interest (AESI)
Time frame:
up to Week 126
Reported as:
Count of participants · Participants
Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI)
ParticipantsTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Infections389398
Infections: Opportunistic Infections1922
Malignancies96
Basal cell carcinoma21
Elevation of Blood Lipids120138
Systemic Injection Reactions and Hypersensitivity Reactions99100
Systemic Injection Reactions and Hypersensitivity Reactions: Anaphylactic Reactions00
Gastrointestinal Perforations12
Neutropenia, Thrombocytopenia, Leukocytopenia and Pancytopenia146168
Potential Hepatotoxicity6863
Injection Site Reactions3434
Demyelination in Peripheral or Central Nervous System01
Autoimmune Disorders4841
PrimaryIncidence of Treatment-Emergent AEs Leading to Withdrawal of the Study Treatment
Time frame:
up to Week 126
Reported as:
Count of participants · Participants
Incidence of Treatment-Emergent AEs Leading to Withdrawal of the Study Treatment
ParticipantsTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Incidence of Treatment-Emergent AEs Leading to Withdrawal of the Study Treatment8790
PrimaryIncidence Rate of Treatment Emergent AEs Per Patient-years of Exposure

Incidence Rate of all Subjects with at Least One Treatment Emergent AE. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.

Time frame:
up to Week 126
Reported as:
Number · subjects per 100 subject-years
Incidence Rate of Treatment Emergent AEs Per Patient-years of Exposure
subjects per 100 subject-yearsOKZ 64 mg q4wOKZ 64 mg q2w
Incidence Rate of Treatment Emergent AEs Per Patient-years of Exposure48.7549.84
PrimaryIncidence Rate of Treatment Emergent SAEs Per Patient-years of Exposure

Incidence Rate of all Subjects with at Least One Treatment Emergent SAE. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.

Time frame:
up to Week 126
Reported as:
Number · subjects per 100 subject-years
Incidence Rate of Treatment Emergent SAEs Per Patient-years of Exposure
subjects per 100 subject-yearsOKZ 64 mg q4wOKZ 64 mg q2w
Incidence Rate of Treatment Emergent SAEs Per Patient-years of Exposure7.747.37
PrimaryIncidence Rate of Treatment Emergent AESIs (Safety Population)

Incidence Rate of all Subjects with at Least One Treatment Emergent AESI. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.

Time frame:
up to Week 126
Reported as:
Number · subjects per 100 subject-years
Incidence Rate of Treatment Emergent AESIs (Safety Population)
subjects per 100 subject-yearsOKZ 64 mg q4wOKZ 64 mg q2w
Incidence Rate of Treatment Emergent AESIs (Safety Population)40.4942.13
SecondaryAmerican College of Rheumatology 20% (ACR20) Response Rates Compare Against Core Baseline Through Week 82

Number and Proportion of subjects achieving an ACR20 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)

Time frame:
up to Week 82
Reported as:
Count of participants · Participants
American College of Rheumatology 20% (ACR20) Response Rates Compare Against Core Baseline Through Week 82
ParticipantsTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Week 12 OLE861863
Week 20 OLE850851
Week 28 OLE839829
Week 40 OLE795795
Week 52 OLE780783
Week 64 OLE777774
Week 82 OLE811830
SecondaryAmerican College of Rheumatology 50% (ACR50) Response Rates Compare Against Core Baseline Through Week 82

Number and Proportion of subjects achieving an ACR50 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82 American College of Rheumatology 50 % response is a composite defined as a ≥ 50% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥ 50% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)

Time frame:
up to Week 82
Reported as:
Count of participants · Participants
American College of Rheumatology 50% (ACR50) Response Rates Compare Against Core Baseline Through Week 82
ParticipantsTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Week 12 OLE598601
Week 20 OLE607607
Week 28 OLE597610
Week 40 OLE600594
Week 52 OLE563606
Week 64 OLE584583
Week 82 OLE608619
SecondaryAmerican College of Rheumatology 70% (ACR70) Response Rates Compare Against Core Baseline Through Week 82

Number and Proportion of subjects achieving an ACR70 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82 American College of Rheumatology 70 % response is a composite defined as a ≥ 70% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥ 70% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)

Time frame:
up to Week 82
Reported as:
Count of participants · Participants
American College of Rheumatology 70% (ACR70) Response Rates Compare Against Core Baseline Through Week 82
ParticipantsTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Week 12 OLE330362
Week 20 OLE358353
Week 28 OLE367357
Week 40 OLE375369
Week 52 OLE370387
Week 64 OLE373387
Week 82 OLE382393
SecondaryProportion of Subjects With Simplified Disease Activity Index (SDAI) Remission Through Week 82

The number and proportion of subjects with SDAI score ≤ 3.3 (considered to be in remission). The SDAI was calculated in the statistical database for analysis purposes using the SJC (28 joints), TJC (28 joints), CRP (mg/dL), the Patient Global Assessment of Disease Activity (VAS) (in cm), and the Physician Global Assessment (VAS) (in cm) according to the following formula: SJC + TJC + Patient Global Assessment of Disease Activity (VAS) + Physician Global Assessment (VAS) + CRP (mg/dL)

Time frame:
up to week 82
Reported as:
Count of participants · Participants
Proportion of Subjects With Simplified Disease Activity Index (SDAI) Remission Through Week 82
ParticipantsTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Core Baseline00
OLE Baseline137145
Week 12 OLE161190
Week 20 OLE192197
Week 28 OLE196196
Week 40 OLE204211
Week 52 OLE218225
Week 64 OLE223257
Week 82 OLE231267
SecondaryDisease Activity Score 28-joint Count (DAS28) Response Rates Through Week 82

Number and Proportion of subjects with DAS28 low disease activity (based on DAS28 C-reactive protein (CRP) \< 3.2), who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82. The DAS28 (CRP) was calculated in the statistical database for analysis purposes using the Swollen joint count (SJC) (28 joints), Tender joint count (TJC) (28 joints), CRP level, and the Patient Global Assessment of Disease Activity Visual Analog Scale (VAS) (100 mm VAS, where 0 is "no disease activity" and 100 was "maximal disease activity") according to the following formula: \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.36 × natural log (CRP+1)\] + \[0.014 × VAS\] + 0.96.

Time frame:
up to Week 82
Reported as:
Count of participants · Participants
Disease Activity Score 28-joint Count (DAS28) Response Rates Through Week 82
ParticipantsTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Core Baseline11
OLE Baseline573537
Week 12 OLE681685
Week 20 OLE703714
Week 28 OLE684694
Week 40 OLE688691
Week 52 OLE679680
Week 64 OLE681678
Week 82 OLE706712
SecondaryChange in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 12

HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

Time frame:
Core baseline, Week 12
Reported as:
Mean · score on a scale
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 12
score on a scaleTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Core Baseline1.70 ± 0.5811.74 ± 0.561
Week 12 OLE1.03 ± 0.6321.00 ± 0.628
Change from Core Baseline-0.67 ± 0.628-0.74 ± 0.648
SecondaryChange in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 20

HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

Time frame:
Core baseline, Week 20
Reported as:
Mean · score on a scale
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 20
score on a scaleTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Core Baseline1.70 ± 0.5811.74 ± 0.561
Week 20 OLE1.00 ± 0.6470.99 ± 0.621
Change from Core Baseline-0.70 ± 0.631-0.74 ± 0.640
SecondaryChange in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 28

HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

Time frame:
Core baseline, Week 28
Reported as:
Mean · score on a scale
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 28
score on a scaleTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Core Baseline1.70 ± 0.5811.74 ± 0.561
Week 28 OLE0.99 ± 0.6320.99 ± 0.627
Change from Core Baseline-0.71 ± 0.645-0.75 ± 0.652
SecondaryChange in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 40

HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

Time frame:
Core baseline, Week 40
Reported as:
Mean · score on a scale
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 40
score on a scaleTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Core Baseline1.70 ± 0.5811.74 ± 0.561
Week 40 OLE0.97 ± 0.6510.99 ± 0.635
Change from Core Baseline-0.72 ± 0.663-0.75 ± 0.672
SecondaryChange in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 52

HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

Time frame:
Core baseline, Week 52
Reported as:
Mean · score on a scale
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 52
score on a scaleTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Core Baseline1.70 ± 0.5811.74 ± 0.561
Week 52 OLE0.97 ± 0.6530.96 ± 0.623
Change from Core Baseline-0.72 ± 0.670-0.77 ± 0.671
SecondaryChange in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 64

HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

Time frame:
Core baseline, Week 64
Reported as:
Mean · score on a scale
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 64
score on a scaleTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Core Baseline1.70 ± 0.5811.74 ± 0.561
Week 64 OLE0.95 ± 0.6410.97 ± 0.635
Change from Core Baseline-0.74 ± 0.643-0.77 ± 0.671
SecondaryChange in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 82

HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

Time frame:
Core baseline, Week 82
Reported as:
Mean · score on a scale
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 82
score on a scaleTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Core Baseline1.70 ± 0.5811.74 ± 0.561
Week 82 OLE0.97 ± 0.6670.98 ± 0.667
Change from Core Baseline-0.72 ± 0.680-0.74 ± 0.695
SecondaryProportion of Subjects With Health Assessment Questionnaire - Disability Index (HAQ-DI) Improvement Through Week 82

The number and proportion of subjects with HAQ-DI improvement ≥ 0.22 Against OLE Baseline. HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.

Time frame:
up to week 82
Reported as:
Count of participants · Participants
Proportion of Subjects With Health Assessment Questionnaire - Disability Index (HAQ-DI) Improvement Through Week 82
ParticipantsTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Week 12 OLE297324
Week 20 OLE319341
Week 28 OLE326320
Week 40 OLE310333
Week 52 OLE322338
Week 64 OLE317326
Week 82 OLE326373
SecondaryChanges From Core Baseline Over Time in Clinical Disease Activity Index (CDAI)

CDAI Range: 0 (the best outcome) - 76 (the worst outcome), with a decrease from baseline indicating improvement. The CDAI was calculated in the statistical database for analysis purposes using the SJC (28 joints), TJC (28 joints), the Patient Global Assessment of Disease Activity (VAS) (in cm), and the Physician Global Assessment (VAS) (in cm) according to the following formula: CDAI = SJC + TJC + Patient Global Assessment of Disease Activity (VAS) + Physician Global Assessment (VAS)

Time frame:
up to week 82
Reported as:
Mean · index units
Changes From Core Baseline Over Time in Clinical Disease Activity Index (CDAI)
index unitsTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Core Baseline Actual Values40.20 ± 11.25240.06 ± 11.605
Week 12 OLE Actual Values10.92 ± 9.34910.54 ± 9.106
Change from Core Baseline at week 12-29.35 ± 12.093-29.54 ± 12.946
Week 20 OLE Actual Values10.30 ± 9.4899.90 ± 8.755
Change from Core Baseline at week 20-29.87 ± 12.553-30.23 ± 12.821
Week 28 OLE Actual Values9.77 ± 8.5839.85 ± 8.696
Change from Core Baseline at week 28-30.35 ± 12.111-30.36 ± 12.849
Week 40 OLE Actual Values9.19 ± 8.4989.34 ± 8.235
Change from Core Baseline at week 40-30.88 ± 11.992-30.80 ± 13.025
Week 52 OLE Actual Values8.69 ± 7.9548.61 ± 7.776
Change from Core Baseline at week 52-31.35 ± 11.855-31.60 ± 12.639
Week 64 OLE Actual Values8.42 ± 7.9978.36 ± 7.798
Change from Core Baseline at week 64-31.68 ± 11.896-31.85 ± 12.484
Week 82 OLE Actual Values9.66 ± 10.5139.36 ± 10.236
Change from Core Baseline at week 82-30.48 ± 12.878-30.58 ± 14.404

Adverse events

Collected over Adverse events (AEs) and serious adverse events (SAEs) were reported from OLE Baseline (the same visit as the Week 24 visit in the core studies) until the end of the follow-up period (safety follow-up (SFU-3)). Any AE, including any AE still ongoing at the end of the study, was to be followed until it had resolved, it had a stable sequelae, the Investigator determined that it was no longer clinically significant, or the subject was lost to follow-up.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Arm 1: OKZ 64 mg q4w + MTX13/1,043 (1.2%)129/1,043 (12.4%)356/1,043 (34.1%)
Treatment Arm 2: OKZ 64 mg q2w + MTX13/1,061 (1.2%)120/1,061 (11.3%)386/1,061 (36.4%)
Most frequent serious events
Showing 10 of 205
Most frequent serious events
EventTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
PneumoniaInfections and infestations7/10437/1061
CellulitisInfections and infestations7/10434/1061
Alanine aminotransferase increasedInvestigations7/10435/1061
OsteoarthritisMusculoskeletal and connective tissue disorders6/10436/1061
ErysipelasInfections and infestations5/10434/1061
Cerebrovascular accidentNervous system disorders4/10432/1061
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/10434/1061
Acute myocardial infarctionCardiac disorders3/10430/1061
COVID-19Infections and infestations1/10433/1061
SepsisInfections and infestations0/10433/1061
Most frequent other events
Most frequent other events
EventTreatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTX
Alanine aminotransferase increasedInvestigations95/1043115/1061
NasopharyngitisInfections and infestations71/104387/1061
Upper respiratory tract infectionInfections and infestations59/104367/1061
Aspartate aminotransferase increasedInvestigations52/104363/1061
BronchitisInfections and infestations59/104345/1061
LeukopeniaBlood and lymphatic system disorders46/104360/1061
NeutropeniaBlood and lymphatic system disorders42/104357/1061
LymphopeniaBlood and lymphatic system disorders41/104350/1061
HypertensionVascular disorders32/104344/1061
HypercholesterolaemiaMetabolism and nutrition disorders25/104342/1061

Baseline characteristics

Subjects who received OKZ in the core study received the same OKZ treatment regimen in the OLE study. Subjects who received in the core study placebo or adalimumab were randomized 1:1 to OKZ 64 mg q2w or OKZ 64 mg q4w regimens in the OLE study. The mITT population included all subjects who signed an ICF for participation in the OLE study, were randomized in the OLE study, received at least 1 dose of study treatment in the OLE study (1057 subjects (OKZ 64 mg q4w), 1047 subjects (OKZ 64 mg q2w)).

Age, Continuous
Age, Continuous(years)Treatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTXTotal
Mean53.7 ± 12.0553.7 ± 11.7853.7 ± 11.91
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTXTotal
Female8518401691
Male206207413
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTXTotal
Hispanic or Latino357332689
Not Hispanic or Latino7007151415
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTXTotal
Asian151732
Black or African American314677
White9148961810
Other/Mixed9788185
Region of Enrollment
Region of Enrollment(Participants)Treatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTXTotal
Colombia323264
Argentina8173154
Hungary313667
United States150155305
Czechia10594199
United Kingdom369
Belarus9918
Russia217208425
Latvia123
South Korea6612
Taiwan448
Brazil5561116
Poland138133271
Mexico137127264
Bulgaria364177
Lithuania293867
Germany162036
Estonia729
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Treatment Arm 1: OKZ 64 mg q4w + MTXTreatment Arm 2: OKZ 64 mg q2w + MTXTotal
Mean28.201 (14.88 to 56.25)28.229 (15.62 to 62.22)28.215 (14.88 to 62.22)
08

Study locations

239 sites
  • AZ Arthritis & Rheum' Research
    Mesa, Arizona 85210, United States
  • Arizona Arthritis & Rheumatology Associates, P.C.
    Phoenix, Arizona 85032, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Sun City, Arizona 85351, United States
  • CHI St. Vincent Hot Springs
    Hot Springs, Arkansas 71913, United States
  • Medvin Clinical Research
    Covina, California 91722, United States
  • C.V Mehta MD Med Corp..
    Hemet, California 92543, United States
  • Advanced Medical Research, LLC
    La Palma, California 90623, United States
  • Valerius Medical Group
    Los Alamitos, California 90720-5403, United States
  • Stanford University School of Medicine
    Palo Alto, California 94304, United States
  • Rheumatology Center of San Diego
    San Diego, California 92128, United States
  • East Bay Rheumatology Medical Group, Inc.
    San Leandro, California 94578, United States
  • Inland Rheumatology Clinical Trials, Inc.
    Upland, California 91786, United States
  • Center for Rheumatology Research, Comprehensive Rheumatology Center
    West Hills, California 91307, United States
  • Medvin Clinical Research
    Whittier, California 90602, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230, United States
  • New England Research Associates LLC
    Bridgeport, Connecticut 06606, United States
  • Javed Rheumatology Associates
    Newark, Delaware 19713, United States
  • RASF - Clinical Research Center
    Boca Raton, Florida 33486, United States
  • Reliable Clinical Research, LLC
    Hialeah, Florida 33012, United States
  • Pharmax Research Clinic
    Miami, Florida 33126, United States
  • Medical Research Center of Miami
    Miami, Florida 33134, United States
  • Suncoast Research Group, LLC
    Miami, Florida 33135, United States
  • Omega Research Consultants
    Orlando, Florida 32810, United States
  • Arthritis Research of Florida, INC
    Palm Harbor, Florida 34684, United States
  • Family Clinical Trials, LLC.
    Pembroke Pines, Florida 33026, United States
  • AdventHealth Medical Group, PA
    Tampa, Florida 33614, United States
  • Lovelace Scientific Resources, Inc.
    Venice, Florida 34292, United States
  • Arthritis Center of North Georgia
    Gainesville, Georgia 30501, United States
  • Marietta Rheumatology Associates, PC
    Marietta, Georgia 30060, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • Graves Gilbert Clinic
    Bowling Green, Kentucky 42101, United States
  • The Arthritis & Diabetes Clinic, Inc.
    Monroe, Louisiana 71203, United States
  • Klein and Associates, M.D., P.A.
    Hagerstown, Maryland 21740, United States
  • The Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • AA MRC LLC Ahmed Arif Medical Research Center
    Grand Blanc, Michigan 48439, United States
  • North MS Medical Clinics, Inc.
    Tupelo, Mississippi 38801, United States
  • Glacier View Research Institute-Rheumatology
    Kalispell, Montana 59901, United States
  • Physician Research Collaboration
    Lincoln, Nebraska 68516, United States
  • Arthritis & Osteoporosis Associates, PA
    Freehold, New Jersey 07728, United States
  • Lovelace Scientific Resources, Inc.
    Albuquerque, New Mexico 87114, United States
  • NYU Langone ambulatory care
    Brooklyn, New York 11201, United States
  • Medication Management, LLC
    Greensboro, North Carolina 27408, United States
  • Cape Fear Arthritis Care
    Leland, North Carolina 28451, United States
  • Carolina Arthritis Associates
    Wilmington, North Carolina 28401, United States
  • Trinity Medical Group
    Minot, North Dakota 58701, United States
  • Cincinnati Rheumatic Disease Study Group
    Cincinnati, Ohio 45242, United States
  • STAT Research, Inc.
    Dayton, Ohio 45417, United States
  • Clinical Research Source, Inc.
    Toledo, Ohio 43606, United States
  • Health Research of Oklahoma, PLLC
    Oklahoma City, Oklahoma 73103, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Altoona Center for Clinical Research, P.C.
    Duncansville, Pennsylvania 16635, United States
  • Arthritis Group
    Philadelphia, Pennsylvania 19152, United States
  • Low Country Rheumatology, PA
    Summerville, South Carolina 29486, United States
  • Amarillo Center for Clinical Research
    Amarillo, Texas 79124, United States
  • Austin Regional Clinic, P.A.
    Austin, Texas 78731, United States
  • Accurate Clinical Management., LLC
    Baytown, Texas 77521, United States
  • Precision Comprehensive Clinical Research Solutions
    Colleyville, Texas 76034, United States
  • Pioneer Research Solutions, Inc.
    Cypress, Texas 77429, United States
  • Therapeutic Concepts Rheumatology,LLC
    Houston, Texas 77004, United States
  • Rheumatology Clinic of Houston, P.A.
    Houston, Texas 77065, United States
  • Houston Institute For Clinical Research
    Houston, Texas 77074, United States
  • Accurate Clinical Mangemnt - Partner
    Houston, Texas 77089, United States
  • Accurate Clinical Research, Inc.
    Houston, Texas 77089, United States
  • Accurate Clinical Research, Inc.
    League City, Texas 77573, United States
  • West Texas Clinical Research
    Lubbock, Texas 79410, United States
  • Dr Alex De Jesus Rheumatology, P.A.
    San Antonio, Texas 78229, United States
  • Advanced Rheumatology of Houston
    The Woodlands, Texas 77382, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Arthritis Northwest, PLLC
    Spokane, Washington 99204, United States
  • Centro de Investigaciones Medicas Mar del Plata
    Mar del Plata, Buenos Aires B7600FYK, Argentina
  • Instituto Medico CER
    Quilmes, Buenos Aires B1878DVB, Argentina
  • Instituto de Investigaciones Clinicas Quilmes
    Quilmes, Buenos Aires B1878GEG, Argentina
  • Sanatorio San Martin
    Venado Tuerto, Santa Fe S2600KUE, Argentina
  • Centro Medico Privado de Reumatologia
    San Miguel de Tucuman, Tucuman T4000AXL, Argentina
  • Instituto de Investigaciones Clinicas-Mar del Plata
    Buenos Aires, B7600FZN, Argentina
  • Organizacion Medica de Investigacion (OMI)
    Ciudad Autonoma Buenos Aires, C1015ABO, Argentina
  • APRILLUS Asistencia e Investigacion
    Ciudad Autonoma Buenos aires, C1046AAQ, Argentina
  • Instituto Centenario
    Ciudad Autonoma Buenos Aires, C1204AAD, Argentina
  • Hospital Privado Centro Medico de Cordoba
    Cordoba, 5016, Argentina
  • Instituto DAMIC Fundacion Rusculleda
    Córdoba, X5003DCE, Argentina
  • CER San Juan Centro Polivalente de Asistencia e Inv. Clinica
    San Juan, 5400, Argentina
  • Clinica de Higado y Aparato Digestivo
    Santa Fe, S2000CFJ, Argentina
  • Centro de Investigaciones Reumatológicas
    Tucuman, T4000BRD, Argentina
  • Minsk City Clinical Hospital #1
    Minsk, Minsk Oblast 220013, Belarus
  • Vitebsk Clinical Hospital
    Vitebsk, Vitebsk Oblast 210037, Belarus
  • HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará
    Fortaleza, Ceará 60430-370, Brazil
  • CEDOES - Diagnóstico e Pesquisa
    Vitória, Espírito Santo 29055-450, Brazil
  • CIP - Centro Internacional de Pesquisa
    Goiânia, Goiás 74110-120, Brazil
  • CMiP - Centro Mineiro de Pesquisa
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • CETI - Centro de Estudos em Terapias Inovadoras Ltda.
    Curitiba, Paraná 80030-110, Brazil
  • Clinilive - Clínica do Idoso e Pesquisa Clínica
    Maringá, Paraná 87013-250, Brazil
  • Hospital Bruno Born
    Lajeado, Rio Grande Do Sul 95900-010, Brazil
  • LMK Serviços Médicos S/S Ltda
    Pôrto Alegre, Rio Grande Do Sul 90480-000, Brazil
  • Clínica de Neoplasias Litoral Ltda.
    Itajaí, Santa Catarina 88301-215, Brazil
  • Faculdade de Medicina do ABC
    Santo André, Sao Paulo 09060-650, Brazil
  • Centro Multidisciplinar de Estudos Clínicos - CEMEC
    Sao Bernardo Do Campo, Sao Paulo 09715-090, Brazil
  • CCBR Brasil Centro de Pesquisas e Análises Clínicas Ltda.
    Rio de Janeiro, 20241-180, Brazil
  • CPCLIN - Centro de Pesquisas Clínicas Ltda.
    São Paulo, 01228-200, Brazil

Showing the first 100 of 239 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Sep 2021, 49 months.

Results were first posted in Jun 2022, 9 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 49 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2017
First posted
Apr 19, 2017
StartActual
Jul 4, 2017
Primary completionActual
Sep 1, 2021
CompletionActual
Sep 1, 2021
Results first posted
Jun 7, 2022
Last update
Oct 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03120949
Collaborators
IQVIA Pvt. Ltd, OCT Clinical Trials
Responsible party
Sponsor
First posted
Apr 19, 2017
Start date
Jul 4, 2017
Primary completion
Sep 1, 2021
Completion
Sep 1, 2021
Results posted
Jun 7, 2022
Last update
Oct 12, 2023

Study contacts

Mikhail Samsonov
study director · Chief Medical Officer, R-Pharm

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olokizumab

Start the discussion